Search

Your search keyword '"DiSilvestro, P.A."' showing total 103 results
Start Over Author "DiSilvestro, P.A."
103 results on '"DiSilvestro, P.A."'

1. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe

Author

Levenback, C.F., Hermans, R.H., Bouda, J., Sharma, A., Luesley, D., Ellis, P., Cruickshank, D.J., Duncan, T.J., Kieser, K., Palle, C., Spirtos, N.M., O'Malley, D.M., Leitao, M.M., Geller, M., Dhar, K., Asher, V., Tobias, D.H., Borgfeldt, C., Lea, J.S., Lood, M., Bailey, J., Eyjolfsdottir, B., Attard-Montalto, S., Tewari, K.S., Persson, P., Manchanda, R., Jensen, P., Van Le, L., Van der Kolk, W.L., Van der Zee, A.G.J., Slomovitz, B.M., Baldwin, P.J.W., Van Doorn, H.C., De Hullu, J.A., Van der Velden, J., Gaarenstroom, K.N., Slangen, B.F.M., Kjolhede, P., Brännström, M., Vergote, I., Holland, C.M., Coleman, R., Van Dorst, E.B.L., Van Driel, W.J., Nunns, D., Widschwendter, M., Nugent, D., DiSilvestro, P.A., Mannel, R.S., Tjiong, M.Y., Boll, D., Cibula, D., Covens, A., Provencher, D., Runnebaum, I.B., Monk, B.J., Zanagnolo, V., Tamussino, K., and Oonk, M.H.M.

Published
2022
Full Text
View/download PDF

2. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe

Author

Van der Kolk, W.L., primary, Van der Zee, A.G.J., additional, Slomovitz, B.M., additional, Baldwin, P.J.W., additional, Van Doorn, H.C., additional, De Hullu, J.A., additional, Van der Velden, J., additional, Gaarenstroom, K.N., additional, Slangen, B.F.M., additional, Kjolhede, P., additional, Brännström, M., additional, Vergote, I., additional, Holland, C.M., additional, Coleman, R., additional, Van Dorst, E.B.L., additional, Van Driel, W.J., additional, Nunns, D., additional, Widschwendter, M., additional, Nugent, D., additional, DiSilvestro, P.A., additional, Mannel, R.S., additional, Tjiong, M.Y., additional, Boll, D., additional, Cibula, D., additional, Covens, A., additional, Provencher, D., additional, Runnebaum, I.B., additional, Monk, B.J., additional, Zanagnolo, V., additional, Tamussino, K., additional, Oonk, M.H.M., additional, Levenback, C.F., additional, Hermans, R.H., additional, Bouda, J., additional, Sharma, A., additional, Luesley, D., additional, Ellis, P., additional, Cruickshank, D.J., additional, Duncan, T.J., additional, Kieser, K., additional, Palle, C., additional, Spirtos, N.M., additional, O'Malley, D.M., additional, Leitao, M.M., additional, Geller, M., additional, Dhar, K., additional, Asher, V., additional, Tobias, D.H., additional, Borgfeldt, C., additional, Lea, J.S., additional, Lood, M., additional, Bailey, J., additional, Eyjolfsdottir, B., additional, Attard-Montalto, S., additional, Tewari, K.S., additional, Persson, P., additional, Manchanda, R., additional, Jensen, P., additional, and Van Le, L., additional

Published
2022
Full Text
View/download PDF

3. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe

Author

Kolk, W.L. Van der, Zee, A.G. van der, Slomovitz, B.M., Baldwin, P.J., Doorn, H.C. van, Hullu, J.A. de, Velden, J van der, Gaarenstroom, K.N., Slangen, B.F.M., Kjolhede, P., Brännström, M., Vergote, I., Holland, C.M., Coleman, R., Dorst, E.B. van, Driel, W.J. van, Nunns, D., Widschwendter, M., Nugent, D., DiSilvestro, P.A., Mannel, R.S., Tjiong, M.Y., Boll, D., Cibula, D., Covens, A., Provencher, D., Runnebaum, I.B., Monk, B.J., Zanagnolo, V., Tamussino, K., Oonk, M.H., Kolk, W.L. Van der, Zee, A.G. van der, Slomovitz, B.M., Baldwin, P.J., Doorn, H.C. van, Hullu, J.A. de, Velden, J van der, Gaarenstroom, K.N., Slangen, B.F.M., Kjolhede, P., Brännström, M., Vergote, I., Holland, C.M., Coleman, R., Dorst, E.B. van, Driel, W.J. van, Nunns, D., Widschwendter, M., Nugent, D., DiSilvestro, P.A., Mannel, R.S., Tjiong, M.Y., Boll, D., Cibula, D., Covens, A., Provencher, D., Runnebaum, I.B., Monk, B.J., Zanagnolo, V., Tamussino, K., and Oonk, M.H.

Abstract

Contains fulltext : 282897.pdf (Publisher’s version ) (Open Access), OBJECTIVE: Optimal management of the contralateral groin in patients with early-stage vulvar squamous cell carcinoma (VSCC) and a metastatic unilateral inguinal sentinel lymph node (SN) is unclear. We analyzed patients who participated in GROINSS-V I or II to determine whether treatment of the contralateral groin can safely be omitted in patients with a unilateral metastatic SN. METHODS: We selected the patients with a unilateral metastatic SN from the GROINSS-V I and II databases. We determined the incidence of contralateral additional non-SN metastases in patients with unilateral SN-metastasis who underwent bilateral inguinofemoral lymphadenectomy (IFL). In those who underwent only ipsilateral groin treatment or no further treatment, we determined the incidence of contralateral groin recurrences during follow-up. RESULTS: Of 1912 patients with early-stage VSCC, 366 had a unilateral metastatic SN. Subsequently, 244 had an IFL or no treatment of the contralateral groin. In seven patients (7/244; 2.9% [95% CI: 1.4%-5.8%]) disease was diagnosed in the contralateral groin: five had contralateral non-SN metastasis at IFL and two developed an isolated contralateral groin recurrence after no further treatment. Five of them had a primary tumor ≥30 mm. Bilateral radiotherapy was administered in 122 patients, of whom one (1/122; 0.8% [95% CI: 0.1%-4.5%]) had a contralateral groin recurrence. CONCLUSION: The risk of contralateral lymph node metastases in patients with early-stage VSCC and a unilateral metastatic SN is low. It appears safe to limit groin treatment to unilateral IFL or inguinofemoral radiotherapy in these cases.

Published
2022

5. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II

Author

Oonk, M.H., Slomovitz, B., Baldwin, P.J., Doorn, H.C. van, Velden, J. van der, Hullu, J.A. de, Gaarenstroom, K.N., Slangen, B.F.M., Vergote, I., Brännström, M., Dorst, E.B.L. van, Driel, W.J. van, Hermans, R.H., Nunns, D., Widschwendter, M., Nugent, D., Holland, C.M., Sharma, A., DiSilvestro, P.A., Mannel, R., Boll, D., Cibula, D., Covens, A., Provencher, D., Runnebaum, I.B., Luesley, D., Ellis, P., Duncan, T.J., Tjiong, M.Y., Cruickshank, D.J., Kjølhede, P., Levenback, C.F., Bouda, J., Kieser, K.E., Palle, C., Spirtos, N.M., O'Malley, D.M., Leitao, M.M., Geller, M.A., Dhar, K., Asher, V., Tamussino, K., Tobias, D.H., Borgfeldt, C., Lea, J.S., Bailey, J., Lood, M., Eyjolfsdottir, B., Attard-Montalto, S., Tewari, K.S., Manchanda, R., Jensen, P.T., Persson, P., Le, L, Putter, H., Bock, G.H. de, Monk, B.J., Creutzberg, C.L., Zee, A.G. van der, Oonk, M.H., Slomovitz, B., Baldwin, P.J., Doorn, H.C. van, Velden, J. van der, Hullu, J.A. de, Gaarenstroom, K.N., Slangen, B.F.M., Vergote, I., Brännström, M., Dorst, E.B.L. van, Driel, W.J. van, Hermans, R.H., Nunns, D., Widschwendter, M., Nugent, D., Holland, C.M., Sharma, A., DiSilvestro, P.A., Mannel, R., Boll, D., Cibula, D., Covens, A., Provencher, D., Runnebaum, I.B., Luesley, D., Ellis, P., Duncan, T.J., Tjiong, M.Y., Cruickshank, D.J., Kjølhede, P., Levenback, C.F., Bouda, J., Kieser, K.E., Palle, C., Spirtos, N.M., O'Malley, D.M., Leitao, M.M., Geller, M.A., Dhar, K., Asher, V., Tamussino, K., Tobias, D.H., Borgfeldt, C., Lea, J.S., Bailey, J., Lood, M., Eyjolfsdottir, B., Attard-Montalto, S., Tewari, K.S., Manchanda, R., Jensen, P.T., Persson, P., Le, L, Putter, H., Bock, G.H. de, Monk, B.J., Creutzberg, C.L., and Zee, A.G. van der

Abstract

Item does not contain fulltext, PURPOSE: The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS: GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS: From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION: Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macr

Published
2021

9. Does adjuvant treatment increase risk of midurethral sling complications after concomitant surgery for endometrial cancer and stress urinary incontinence?

Author

Kulkarni, A., primary, Proussaloglou, E., additional, Beffa, L.B., additional, Miller, K., additional, Bevis, K.S., additional, Wohlrab, K., additional, Lokich, E., additional, McCourt, C.K., additional, Glaser, G.E., additional, Brown, A.K., additional, Wethington, S.L., additional, Carlson, M.J., additional, DiSilvestro, P.A., additional, Occhino, J.A., additional, Dunivan, G., additional, Tunitsky, E., additional, Chen, G., additional, Raker, C., additional, Luis, C., additional, and Robison, K.M., additional

Published
2020
Full Text
View/download PDF

10. A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study

Author

Bae-Jump, V.L., primary, Sill, M., additional, Gehrig, P.A., additional, Moxley, K., additional, Hagemann, A.R., additional, Waggoner, S.E., additional, O'Cearbhaill, R.E., additional, McDonald, M., additional, DiSilvestro, P.A., additional, Sperduto, P., additional, and Aghajanian, C., additional

Published
2020
Full Text
View/download PDF

11. Sexual dysfunction in women with endometrial cancer and stress urinary incontinence

Author

Proussaloglou, E., primary, Kulkarni, A., additional, Beffa, L.B., additional, Miller, K., additional, Wohlrab, K., additional, Lokich, E., additional, McCourt, C.K., additional, Glaser, G.E., additional, Brown, A.K., additional, Wethington, S.L., additional, Carlson, M.J., additional, DiSilvestro, P.A., additional, Lowder, J.L., additional, Rahn, D.D., additional, Occhino, J.A., additional, Dunivan, G., additional, Chen, G., additional, Raker, C., additional, and Robison, K.M., additional

Published
2020
Full Text
View/download PDF

15. Radiotherapy as an alternative treatment for inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: Results of GROINSS-V II

Author

van Der Zee, A.G., primary, Slomovitz, B., additional, Covens, A.L., additional, van Der Velden, J., additional, de Hullu, J.A., additional, Slangen, B., additional, van Dorst, E., additional, Van Driel, W.J., additional, Hermans, R., additional, Vergote, I.B., additional, Nunns, D., additional, Holland, C., additional, Cibula, D., additional, Mannel, R.S., additional, DiSilvestro, P.A., additional, Provencher, D., additional, Monk, B.J., additional, and Oonk, M., additional

Published
2020
Full Text
View/download PDF

16. Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)

Author

Mileshkin, L., primary, Barnes, E., additional, Moore, K.N., additional, Gebski, V., additional, King, M., additional, Narayan, K., additional, Kolodziej, I.K., additional, Sjoquist, K., additional, Fyles, A., additional, Small, W., additional, Gaffney, D., additional, Quinn, M., additional, Andrews, J., additional, Thompson, S., additional, Huh, W., additional, Carlson, M., additional, Disilvestro, P.A., additional, Rischin, D., additional, Stockler, M.R., additional, and Monk, B.J., additional

Published
2019
Full Text
View/download PDF

17. Distance to referral center and race/ethnicity among women choosing preoperative urogynecology referral: Cancer of the uterus and treatment of incontinence (CUTI) study

Author

Miller, K., primary, Lokich, E., additional, Bevis, K.S., additional, Howe, C., additional, Wohlrab, K., additional, Richter, H., additional, Sung, V., additional, McCourt, C.K., additional, Glaser, G.E., additional, Brown, A.K., additional, Wethington, S., additional, Carlson, M.J., additional, DiSilvestro, P.A., additional, Lowder, J.L., additional, Rahn, D.D., additional, Occhino, J.A., additional, Dunivan, G., additional, Tunitsky, E., additional, Chen, G., additional, Luis, C., additional, Raker, C., additional, Clark, M., additional, and Robison, K.M., additional

Published
2019
Full Text
View/download PDF

18. Opportunities to improve sexual health and quality of life in endometrial cancer survivors

Author

Glaser, G.E., primary, Miller, K., additional, Bevis, K.S., additional, Howe, C., additional, Wohlrab, K., additional, Sung, V., additional, Richter, H., additional, Lokich, E., additional, McCourt, C.K., additional, Brown, A.K., additional, Wethington, S., additional, Carlson, M.J., additional, DiSilvestro, P.A., additional, Lowder, J.L., additional, Rahn, D.D., additional, Occhino, J.A., additional, Dunivan, G., additional, Tunitsky, E., additional, Chen, G., additional, Luis, C., additional, Raker, C., additional, Clark, M., additional, and Robison, K.M., additional

Published
2019
Full Text
View/download PDF

20. Concurrent surgical treatment of urinary incontinence at the time of endometrial cancer surgery is associated with improved quality of life 6 months after cancer surgery: Cancer of the uterus and treatment of incontinence (CUTI) study

Author

Robison, K.M., primary, Bevis, K.S., additional, Howe, C., additional, Wohlrab, K., additional, Sung, V., additional, Richter, H., additional, Lokich, E., additional, McCourt, C.K., additional, Glaser, G.E., additional, Brown, A.K., additional, Wethington, S., additional, Carlson, M.J., additional, DiSilvestro, P.A., additional, Lowder, J.L., additional, Rahn, D.D., additional, Occhino, J.A., additional, Dunivan, G., additional, Tunitsky, E., additional, Chen, G., additional, Luis, C., additional, Raker, C., additional, and Clark, M., additional

Published
2019
Full Text
View/download PDF

21. Adverse outcomes among women after concurrent surgery for endometrial cancer and pelvic floor disorders: The cancer of the uterus and treatment of incontinence (CUTI) trial

Author

Glassman, D., primary, Wohlrab, K., additional, Bevis, K.S., additional, Sung, V., additional, Richter, H., additional, Howe, C., additional, Lokich, E., additional, McCourt, C.K., additional, Glaser, G.E., additional, Brown, A.K., additional, Wethington, S., additional, DiSilvestro, P.A., additional, Lowder, J.L., additional, Occhino, J.A., additional, Dunivan, G., additional, Chen, G., additional, Luis, C., additional, Raker, C., additional, Clark, M., additional, Robison, K.M., additional, Carlson, M.J., additional, and Tunitsky, E., additional

Published
2019
Full Text
View/download PDF

23. Characteristics of women with endometrial cancer and stress urinary incontinence (SUI) that desire concurrent cancer and SUI surgery: Cancer of the uterus and treatment of incontinence (CUTI) study

Author

Robison, K.M., primary, Bevis, K.S., additional, Howe, C., additional, Wohlrab, K., additional, Sung, V., additional, Richter, H., additional, Lokich, E., additional, McCourt, C.K., additional, Glaser, G.E., additional, Brown, A.K., additional, Wethington, S., additional, Carlson, M.J., additional, Rahn, D.D., additional, Lowder, J., additional, Occhino, J., additional, Dunivan, G., additional, Tunitsky, E., additional, Chen, G., additional, Luis, C., additional, Raker, C., additional, DiSilvestro, P.A., additional, and Clark, M., additional

Published
2018
Full Text
View/download PDF

27. Variations in patient preferences over side effects of treatments for ovarian cancer: Baseline results of a randomized controlled clinical trial

Author

Mukamel, D.B., primary, Wenzel, L., additional, Havrilesky, L.J., additional, Osann, K., additional, Ladd, H.A., additional, Walker, J.L., additional, Wright, A.A., additional, Alvarez, R.D., additional, Bristow, R.E., additional, DiSilvestro, P.A., additional, Morgan, R.J., additional, Lipscomb, J., additional, and Cohn, D.E., additional

Published
2017
Full Text
View/download PDF

28. Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: An ancillary study of GOG 262

Author

Chan, J.K., primary, Brady, M.F., additional, Penson, R.T., additional, Monk, B.J., additional, Kapp, D.S., additional, Birrer, M.J., additional, Huang, H., additional, Walker, J.L., additional, DiSilvestro, P.A., additional, Rubin, S.C., additional, Martin, L.P., additional, Davidson, S.A., additional, Huh, W.K., additional, O'Malley, D.M., additional, Boente, M.P., additional, and Michael, H., additional

Published
2017
Full Text
View/download PDF

29. 1052P - Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)

Author

Mileshkin, L., Barnes, E., Moore, K.N., Gebski, V., King, M., Narayan, K., Kolodziej, I.K., Sjoquist, K., Fyles, A., Small, W., Gaffney, D., Quinn, M., Andrews, J., Thompson, S., Huh, W., Carlson, M., Disilvestro, P.A., Rischin, D., Stockler, M.R., and Monk, B.J.

Published
2019
Full Text
View/download PDF

30. Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer

Author

Matulonis, U.A., Monk, B.J., Secord, A.A., Geller, M.A., Miller, D.S., Cloven, N.G., Fleming, G.F., Hendrickson, A.E. Wahner, Azodi, M., DiSilvestro, P.A., Oza, A.M., Cristea, M., Berek, J.S., Chan, J.K., Li, Y., Luptakova, K., Hazard, S.J., and Moore, K.N.

Published
2019
Full Text
View/download PDF

32. Mutations in homologous recombination genes and response to treatment in GOG 218: An NRG Oncology study

Author

Norquist, B.S., primary, Brady, M.F., additional, Harrell, M.I., additional, Walsh, T., additional, Lee, M.K., additional, Gulsuner, S.I., additional, Bernards, S., additional, Casadei, S., additional, Burger, R.A., additional, Davidson, S.A., additional, Mannel, R.S., additional, DiSilvestro, P.A., additional, Lankes, H., additional, Ramirez, N., additional, King, M.C., additional, Birrer, M.J., additional, and Swisher, E.M., additional

Published
2016
Full Text
View/download PDF

33. A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: An NRG Oncology Study

Author

Walker, J., primary, Brady, M.F., additional, DiSilvestro, P.A., additional, Fujiwara, K., additional, Alberts, D., additional, Zheng, W., additional, Tewari, K., additional, Cohn, D.E., additional, Powell, M., additional, Van Le, L., additional, Rubin, S., additional, Davidson, S.A., additional, Gray, H.J., additional, Waggoner, S., additional, Myers, T., additional, Aghajanian, C., additional, Secord, A.A., additional, and Mannel, R.S., additional

Published
2016
Full Text
View/download PDF

34. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.

Author

Blein, S., Bardel, C., Danjean, V., McGuffog, L., Healey, S., Barrowdale, D., Lee, A., Dennis, J., Kuchenbaecker, K.B., Soucy, P., Terry, M.B., Chung, W.K., Goldgar, D.E., Buys, S.S., Janavicius, R., Tihomirova, L., Tung, N., Dorfling, C.M., Rensburg, E.J. van, Neuhausen, S.L., Ding, Y.C., Gerdes, A.M., Ejlertsen, B., Nielsen, F.C., Hansen, T.V., Osorio, A., Benitez, J., Conejero, R.A., Segota, E., Weitzel, J.N., Thelander, M., Peterlongo, P., Radice, P., Pensotti, V., Dolcetti, R., Bonanni, B., Peissel, B., Zaffaroni, D., Scuvera, G., Manoukian, S., Varesco, L., Capone, G.L., Papi, L., Ottini, L., Yannoukakos, D., Konstantopoulou, I., Garber, J., Hamann, U., Donaldson, A., Brady, A., Brewer, C., Foo, C., Evans, D.G., Frost, D., Eccles, D., Douglas, F., Cook, J., Adlard, J., Barwell, J., Walker, L., Izatt, L., Side, L.E., Kennedy, M.J., Tischkowitz, M., Rogers, M.T., Porteous, M.E., Morrison, P.J., Platte, R., Eeles, R., Davidson, R., Hodgson, S., Cole, T., Godwin, A.K., Isaacs, C., Claes, K., Leeneer, K. De, Meindl, A., Gehrig, A., Wappenschmidt, B., Sutter, C., Engel, C., Niederacher, D., Steinemann, D., Plendl, H., Kast, K., Rhiem, K., Ditsch, N., Arnold, N., Varon-Mateeva, R., Schmutzler, R.K., Preisler-Adams, S., Markov, N.B., Wang-Gohrke, S., Pauw, A. de, Lefol, C., Lasset, C., Leroux, D., Rouleau, E., Damiola, F., Dreyfus, H., Barjhoux, L., Golmard, L., Uhrhammer, N., Bonadona, V., Sornin, V., Bignon, Y.J., Carter, J., Le, L, Piedmonte, M., DiSilvestro, P.A., Hoya, M. de la, Caldes, T., Nevanlinna, H., Aittomaki, K., Jager, A., Ouweland, A.M. van den, Kets, C.M., Aalfs, C.M., Leeuwen, F.E. van, Hogervorst, F.B., Meijers-Heijboer, H.E., Oosterwijk, J.C., Roozendaal, K.E. van, Rookus, M.A., Devilee, P., Luijt, R.B. van der, Olah, E., Diez, O., Teule, A., Lazaro, C., Blanco, I., Valle, J., Jakubowska, A., Sukiennicki, G., Gronwald, J., Lubinski, J., Durda, K., Jaworska-Bieniek, K., Agnarsson, B.A., Maugard, C., Amadori, A., Montagna, M., Teixeira, M.R., Spurdle, A.B., Foulkes, W., Olswold, C., Lindor, N.M., Pankratz, V.S., Szabo, C.I., Lincoln, A., Jacobs, L., Corines, M., Robson, M., Vijai, J., Berger, A., Fink-Retter, A., Singer, C.F., Rappaport, C., Kaulich, D.G., Pfeiler, G., Tea, M.K., Greene, M.H., Mai, P.L., Rennert, G., Imyanitov, E.N., Mulligan, A.M., Glendon, G., Andrulis, I.L., Tchatchou, S., Toland, A.E., Pedersen, I.S., Thomassen, M., Kruse, T.A., Jensen, U.B., Caligo, M.A., Friedman, E., Zidan, J., Laitman, Y., Lindblom, A., Melin, B., Arver, B., Loman, N., Rosenquist, R., Olopade, O.I., Nussbaum, R.L., Ramus, S.J., Nathanson, K.L., Domchek, S.M., Rebbeck, T.R., Arun, B.K., Mitchell, G., Karlan, B.Y., Lester, J., Orsulic, S., Stoppa-Lyonnet, D., Thomas, G, Simard, J., Couch, F.J., Offit, K., Easton, D.F., Chenevix-Trench, G., Antoniou, A.C., Mazoyer, S., Phelan, C.M., Sinilnikova, O.M., Cox, D.G., Blein, S., Bardel, C., Danjean, V., McGuffog, L., Healey, S., Barrowdale, D., Lee, A., Dennis, J., Kuchenbaecker, K.B., Soucy, P., Terry, M.B., Chung, W.K., Goldgar, D.E., Buys, S.S., Janavicius, R., Tihomirova, L., Tung, N., Dorfling, C.M., Rensburg, E.J. van, Neuhausen, S.L., Ding, Y.C., Gerdes, A.M., Ejlertsen, B., Nielsen, F.C., Hansen, T.V., Osorio, A., Benitez, J., Conejero, R.A., Segota, E., Weitzel, J.N., Thelander, M., Peterlongo, P., Radice, P., Pensotti, V., Dolcetti, R., Bonanni, B., Peissel, B., Zaffaroni, D., Scuvera, G., Manoukian, S., Varesco, L., Capone, G.L., Papi, L., Ottini, L., Yannoukakos, D., Konstantopoulou, I., Garber, J., Hamann, U., Donaldson, A., Brady, A., Brewer, C., Foo, C., Evans, D.G., Frost, D., Eccles, D., Douglas, F., Cook, J., Adlard, J., Barwell, J., Walker, L., Izatt, L., Side, L.E., Kennedy, M.J., Tischkowitz, M., Rogers, M.T., Porteous, M.E., Morrison, P.J., Platte, R., Eeles, R., Davidson, R., Hodgson, S., Cole, T., Godwin, A.K., Isaacs, C., Claes, K., Leeneer, K. De, Meindl, A., Gehrig, A., Wappenschmidt, B., Sutter, C., Engel, C., Niederacher, D., Steinemann, D., Plendl, H., Kast, K., Rhiem, K., Ditsch, N., Arnold, N., Varon-Mateeva, R., Schmutzler, R.K., Preisler-Adams, S., Markov, N.B., Wang-Gohrke, S., Pauw, A. de, Lefol, C., Lasset, C., Leroux, D., Rouleau, E., Damiola, F., Dreyfus, H., Barjhoux, L., Golmard, L., Uhrhammer, N., Bonadona, V., Sornin, V., Bignon, Y.J., Carter, J., Le, L, Piedmonte, M., DiSilvestro, P.A., Hoya, M. de la, Caldes, T., Nevanlinna, H., Aittomaki, K., Jager, A., Ouweland, A.M. van den, Kets, C.M., Aalfs, C.M., Leeuwen, F.E. van, Hogervorst, F.B., Meijers-Heijboer, H.E., Oosterwijk, J.C., Roozendaal, K.E. van, Rookus, M.A., Devilee, P., Luijt, R.B. van der, Olah, E., Diez, O., Teule, A., Lazaro, C., Blanco, I., Valle, J., Jakubowska, A., Sukiennicki, G., Gronwald, J., Lubinski, J., Durda, K., Jaworska-Bieniek, K., Agnarsson, B.A., Maugard, C., Amadori, A., Montagna, M., Teixeira, M.R., Spurdle, A.B., Foulkes, W., Olswold, C., Lindor, N.M., Pankratz, V.S., Szabo, C.I., Lincoln, A., Jacobs, L., Corines, M., Robson, M., Vijai, J., Berger, A., Fink-Retter, A., Singer, C.F., Rappaport, C., Kaulich, D.G., Pfeiler, G., Tea, M.K., Greene, M.H., Mai, P.L., Rennert, G., Imyanitov, E.N., Mulligan, A.M., Glendon, G., Andrulis, I.L., Tchatchou, S., Toland, A.E., Pedersen, I.S., Thomassen, M., Kruse, T.A., Jensen, U.B., Caligo, M.A., Friedman, E., Zidan, J., Laitman, Y., Lindblom, A., Melin, B., Arver, B., Loman, N., Rosenquist, R., Olopade, O.I., Nussbaum, R.L., Ramus, S.J., Nathanson, K.L., Domchek, S.M., Rebbeck, T.R., Arun, B.K., Mitchell, G., Karlan, B.Y., Lester, J., Orsulic, S., Stoppa-Lyonnet, D., Thomas, G, Simard, J., Couch, F.J., Offit, K., Easton, D.F., Chenevix-Trench, G., Antoniou, A.C., Mazoyer, S., Phelan, C.M., Sinilnikova, O.M., and Cox, D.G.

Abstract

Contains fulltext : 156875.pdf (publisher's version ) (Open Access), INTRODUCTION: Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers. METHODS: We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals. RESULTS: We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has demonstrated an inverse association with familial breast cancer risk. CONCLUSIONS: This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effe

Published
2015

35. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: A Gynecologic Oncology Group study

Author

Landrum, L.M., primary, Brady, W.E., additional, Armstrong, D.K., additional, Moore, K.N., additional, DiSilvestro, P.A., additional, O'Malley, D.M., additional, Tenney, M.E., additional, Rose, P.G., additional, and Fracasso, P.M., additional

Published
2015
Full Text
View/download PDF

38. Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study

Author

Tewari, K.S., primary, Sill, M., additional, Monk, B.J., additional, Penson, R.T., additional, Lankes, H., additional, Leitao, M.M., additional, Ramondetta, L.M., additional, Van Le, L., additional, Richardson, D.L., additional, Landrum, L.M., additional, DiSilvestro, P.A., additional, Behbakht, K., additional, Ueland, F.R., additional, Michael, H., additional, and Birrer, M.J., additional

Published
2015
Full Text
View/download PDF

41. 1A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group trial

Author

McMeekin, D.S., primary, Filiaci, V.L., additional, Aghajanian, C., additional, Cho, J., additional, Kim, J.W., additional, DiSilvestro, P.A., additional, O'Malley, D., additional, Rutherford, T.J., additional, Van Le, L., additional, and Randall, M.E., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results